Brought to you by 
Spectrum gets rights to Hanmi's tumor compound poziotinib; partnership amended
07 Jan 2022
Executive Summary
Spectrum Pharmaceuticals Inc. licensed exclusive global rights (excluding Korea and China) to Hanmi Pharmaceuticals Co. Ltd.’s pan-HER inhibitor poziotinib, which is in Phase II trials for gastric, head and neck, breast, and non-small cell lung cancers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Spectrum gets rights to Hanmi's tumor compound poziotinib; partnership amended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice